These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29968102)

  • 1. [In-label treatment of inflammatory joint diseases].
    Kneitz C; Fiehn C
    Z Rheumatol; 2018 Sep; 77(7):559-568. PubMed ID: 29968102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs.
    Soriano ER; Acosta-Felquer ML; Luong P; Caplan L
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):793-806. PubMed ID: 25488785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
    Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
    Arthritis Rheumatol; 2017 Aug; 69(8):1538-1551. PubMed ID: 28620948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR
    Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
    Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
    Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
    Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
    Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1111-1124. PubMed ID: 28620917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
    Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
    J Arthroplasty; 2017 Sep; 32(9):2628-2638. PubMed ID: 28629905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.
    Acosta Felquer ML; Coates LC; Soriano ER; Ranza R; Espinoza LR; Helliwell PS; FitzGerald O; McHugh N; Roussou E; Mease PJ
    J Rheumatol; 2014 Nov; 41(11):2277-85. PubMed ID: 25362711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Gálvez Muñoz JG; Saiz Cuenca ES; Fry-Smith A
    Cochrane Database Syst Rev; 2011 Feb; (2):CD007649. PubMed ID: 21328299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.